First Time Loading...

Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR

Watchlist Manager
Arrowhead Pharmaceuticals Inc Logo
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Watchlist
Price: 28.6 USD -0.35%
Updated: Mar 29, 2024

Intrinsic Value

ARWR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. [ Read More ]

The intrinsic value of one ARWR stock under the Base Case scenario is 35.05 USD. Compared to the current market price of 28.6 USD, Arrowhead Pharmaceuticals Inc is Undervalued by 18%.

Key Points:
ARWR Intrinsic Value
Base Case
35.05 USD
Undervaluation 18%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Arrowhead Pharmaceuticals Inc

Backtest ARWR Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ARWR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Arrowhead's Year of Expansion and R&D Growth
2024-Q1 Earnings Call

Arrowhead's Year of Expansion and R&D Growth

Arrowhead reported a significant increase in net loss for the quarter ended December 31, 2023, to $132.9 million, up from $41.3 million in the same period the prior year. Revenue was down to $3.6 million from $62.5 million, owing largely to the full recognition of upfront payments from past agreements. Operating expenses rose to $140.1 million due to more advanced clinical candidate development. The quarterly cash burn is projected at $80 to $100 million with nominal future capital expenditures. Key developments include expected Phase 3 results and NDA filing for Plozasiran, multiple clinical readouts, a structured finance initiative, continued collaboration with Takeda and Amgen, and an upcoming adipose-targeted clinical candidate.

Financials

Balance Sheet Decomposition
Arrowhead Pharmaceuticals Inc

Current Assets 237.9m
Cash & Short-Term Investments 220.3m
Other Current Assets 17.6m
Non-Current Assets 388.4m
PP&E 378.3m
Intangibles 9.8m
Other Non-Current Assets 232k
Current Liabilities 63.7m
Accounts Payable 4.5m
Accrued Liabilities 58.8m
Other Current Liabilities 461k
Non-Current Liabilities 402.2m
Other Non-Current Liabilities 402.2m
Efficiency

Earnings Waterfall
Arrowhead Pharmaceuticals Inc

Revenue
181.7m USD
Operating Expenses
-481.1m USD
Operating Income
-299.4m USD
Other Expenses
2.6m USD
Net Income
-296.7m USD

Free Cash Flow Analysis
Arrowhead Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ARWR Profitability Score
Profitability Due Diligence

Arrowhead Pharmaceuticals Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROIC is Increasing
Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
20/100
Profitability
Score

Arrowhead Pharmaceuticals Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

ARWR Solvency Score
Solvency Due Diligence

Arrowhead Pharmaceuticals Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
57/100
Solvency
Score

Arrowhead Pharmaceuticals Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ARWR Price Targets Summary
Arrowhead Pharmaceuticals Inc

Wall Street analysts forecast ARWR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ARWR is 56.49 USD with a low forecast of 28.28 USD and a high forecast of 94.5 USD.

Lowest
Price Target
28.28 USD
1% Downside
Average
Price Target
56.49 USD
98% Upside
Highest
Price Target
94.5 USD
230% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ARWR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ARWR Price
Arrowhead Pharmaceuticals Inc

1M 1M
-11%
6M 6M
+6%
1Y 1Y
+16%
3Y 3Y
-53%
5Y 5Y
+56%
10Y 10Y
+74%
Annual Price Range
28.6
52w Low
21.2
52w High
41.38
Price Metrics
Average Annual Return 52.77%
Standard Deviation of Annual Returns 130.12%
Max Drawdown -77%
Shares Statistics
Market Capitalization 3.5B USD
Shares Outstanding 123 897 000
Percentage of Shares Shorted 8.37%

ARWR Return Decomposition
Main factors of price return

What is price return decomposition?

ARWR News

Other Videos

Company Profile

Arrowhead Pharmaceuticals Inc Logo
Arrowhead Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

3.5B USD

Dividend Yield

0%

Description

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The company is headquartered in Pasadena, California and currently employs 329 full-time employees. The firm uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The firm is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The firm's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.

Contact

CALIFORNIA
Pasadena
177 E Colorado Blvd, Suite 700
+16266964702.0
http://arrowheadpharma.com/

IPO

1993-12-14

Employees

329

Officers

CEO, President & Director
Dr. Christopher R. Anzalone Ph.D.
Chief Financial Officer
Mr. Kenneth A. Myszkowski
COO, General Counsel & Secretary
Mr. Patrick O'Brien J.D., PharmD
Chief of Discovery & Translational Medicine
Dr. James C. Hamilton M.D., MBA
Founder and Founder & Director of Insert Therapeutics Inc & Calando
Dr. Mark M. Davis Ph.D.
Head of Investor Relations & VP
Dr. Vincent Anzalone CFA
Show More
Director of Communications
Mr. Howard Lovy
Chief Medical Scientist
Dr. Bruce D. Given M.D.
Head of Toxicology & VP
Dr. Mark Seefeld
Chief Commercial Officer
Ms. Tracie Oliver
Show Less

See Also

Discover More
What is the Intrinsic Value of one ARWR stock?

The intrinsic value of one ARWR stock under the Base Case scenario is 35.05 USD.

Is ARWR stock undervalued or overvalued?

Compared to the current market price of 28.6 USD, Arrowhead Pharmaceuticals Inc is Undervalued by 18%.